Androgen deficiency and mitochondrial dysfunction: Implications for fatigue., muscle dysfunction., insulin resistance., diabetes, and cardiovascular disease

Hormone Molecular Biology and Clinical Investigation

Volumn 8, Issue 1, 2011, Pages 431-444

  Traish, Abdulmaged M ^a   Abdallah, Bassima ^a   Yu, George ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

cardiovascular risk; insulin resistance; mitochondria; testosterone deficiency; type 2 diabetes

Indexed keywords

ANDROGEN; FATTY ACID; MITOCHONDRIAL ENZYME; TESTOSTERONE;

AEROBIC METABOLISM; ANDROGEN DEFICIENCY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME ACTIVITY; FATIGUE; FATTY ACID METABOLISM; HORMONE ACTION; HUMAN; INSULIN RESISTANCE; METABOLIC SYNDROME X; MITOCHONDRIAL BIOGENESIS; MITOCHONDRION; MUSCLE DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

EID: 84880918401     PISSN: 18681883     EISSN: 18681891     Source Type: Journal    
DOI: 10.1515/HMBCI.2011.132     Document Type: Article

References (123)

1. Khaw KT., Dowsett M., Folkerd E., Bingham S., Wareham N., Luben R., Welch A., Day N. Endogenous testosterone and mortality due to all causes., cardiovascular disease., and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 2007;116: 2694-701.
2. Laughlin GA., Barrett-Connor E., Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 2008;93:68-75.
3. Tivesten A., Vandenput L., Labrie F., Karlsson MK., Ljunggren O., Mellstrom D., Ohlsson C. Low serum testosterone and estra-diol predict mortality in elderly men. J Clin Endocrinol Metab 2009;94:2482-8.
4. Shores MM., Matsumoto AM., Sloan KL., Kivlahan DR. Low serum testosterone and mortality in male veterans. Arch Intern Med 2006;166:1660-5.
5. Haring R., Völzke H., Felix SB., Schipf S., Dörr M., Rosskopf D., Nauck M., Schöfl C., Wallaschofski H. Prediction of metabolic syndrome by low serum testosterone levels in men: results from the study of health in Pomerania. Diabetes 2009;58:2027-31.
6. Malkin CJ., Channer KS., Jones TH. Testosterone and heart failure. Curr Opin Endocrinol Diabetes Obes 2010;17:262-8.
7. Jones TH. Testosterone deficiency: a risk factor for cardiovascular disease? Trends Endocrinol Metab 2010;21:496-503.
8. Malkin CJ., Pugh PJ., Morris PD., Asif S., Jones TH., Channer KS. Low serum testosterone and increased mortality in men with coronary heart disease. Heart 2010;96:1821-5.
9. Caminiti G., Volterrani M., Iellamo F., Marazzi G., Massaro R., Miceli M., Mammi C., Piepoli M., Fini M., Rosano GM. Effect of long-acting testosterone treatment on functional exercise capacity., skeletal muscle performance., insulin resistance., and barore-flex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol 2009;54:919-27.
10. Coats AJ., Clark AL., Piepoli M., Volterrani M., Poole-Wilson PA. Symptoms and quality of life in heart failure: the muscle hypothesis. Br Heart J 1994;72:S36-9.
11. Piepoli M., Clark AL., Volterrani M., Adamopoulos S., Sleight P., Coats AJ. Contribution of muscle afferents to the hemodynamic., autonomic, and ventilatory responses to exercise in patients with chronic heart failure: effects of physical training. Circulation 1996;93:940-52.
12. Piepoli MF., Kaczmarek A., Francis DP., Davies LC., Rauchhaus M., Jankowska EA., Anker SD., Capucci A., Banasiak W., Ponikowski P. Reduced peripheral skeletal muscle mass and abnormal reflex physiology in chronic heart failure. Circulation 2006;114:126-34.
13. Traish AM., Kypreos KE. Testosterone and cardiovascular disease: an old idea with modern clinical implications. Atherosclerosis 2011;214:244-8.
14. Zitzmann M. Testosterone deficiency., insulin resistance and the metabolic syndrome. Nat Rev Endocrinol 2009;5:673-81.
15. Saad F. The relationship between testosterone deficiency and frailty in elderly men. Horm Mol Biol Clin Invest 2010;4: 529-38.
16. Jockenhövel F., Minnemann T., Schubert M., Freude S., Hübler D., Schumann C., Christoph A., Ernst M. Comparison of long-acting testosterone undecanoate formulation versus testosterone enan-thate on sexual function and mood in hypogonadal men. Eur J Endocrinol 2009;160:815-9.
17. Jockenhövel F., Minnemann T., Schubert M., Freude S., Hübler D., Schumann C., Christoph A., Gooren L., Ernst M. Timetable of effects of testosterone administration to hypogonadal men on variables of sex and mood. Aging Male 2009;12:113-8.
18. Kalinchenko SY., Tishova YA., Mskhalaya GJ., Gooren LJ., Giltay EJ., Saad F. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol (Oxf) 2010;73: 602-12.
19. Tibblin G., Adlerberth A., Lindstedt G., Björntorp P. The pituitary-gonadal axis and health in elderly men: a study of men born in 1913. Diabetes 1996;45:1605-9.
20. Haffner SM., Karhapää P., Mykkänen L., Laakso M. Insulin resistance., body fat distribution., and sex hormones in men. Diabetes 1994;43:212-9.
21. Haffner SM., Shaten J., Stern MP., Smith GD., Kuller L. Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men. MRFIT Research Group. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996;143:889-97.
22. Stellato RK., Feldman HA., Hamdy O., Horton ES., McKinlay JB. Testosterone., sex hormone-binding globulin., and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care 2000;23:490-4.
23. Oh JY., Barrett-Connor E., Wedick NM., Wingard DL. Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. Diabetes Care 2002;25:55-60.
24. Svartberg J., Jenssen T., Sundsfjord J., Jorde R. The associations of endogenous testosterone and sex hormone-binding globulin with glycosylated hemoglobin levels., in community dwelling men. The Tromso Study. Diabetes Metab 2004;30:29-34.
25. Laaksonen DE., Niskanen L., Punnonen K., Nyyssonen K., Tuomainen TP., Valkonen VP., Salonen R., Salonen JT. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004;27:1036-41.
26. Smith JC., Bennett S., Evans LM., Kynaston HG., Parmar M., Mason MD., Cockcroft JR., Scanlon MF., Davies JS. The effects of induced hypogonadism on arterial stiffness., body composition., and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 2001;86:4261-7.
27. Dockery F., Bulpitt CJ., Agarwal S., Donaldson M., Rajkumar C. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond) 2003;104:195-201.
28. D'Amico AV., Denham JW., Crook J., Chen MH., Goldhaber SZ., Lamb DS., Joseph D., Tai KH., Malone S., Ludgate C., Steigler A., Kantoff PW. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007;25:2420-5.
29. Tsai HK., D'Amico AV., Sadetsky N., Chen MH., Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 2007;99:1516-24.
30. Greenfield DM., Walters SJ., Coleman RE., Hancock BW., Snowden JA., Shalet SM., DeRogatis LR., Ross RJ. Quality of life., self-esteem, fatigue., and sexual function in young men after cancer: a controlled cross-sectional study. Cancer 2010;116:1592-601.
31. O'Connor PJ. Evaluation of four highly cited energy and fatigue mood measures. J Psychosom Res 2004;57:435-41.
32. Bjorntorp P. Metabolic implications of body fat distribution. Diabetes Care 1991;14:1132-43.
33. Pitteloud N., Mootha VK., Dwyer AA., Hardin M., Lee H., Eriksson KF., Tripathy D., Yialamas M., Groop L., Elahi D., Hayes FJ. Relationship between testosterone levels., insulin sensitivity., and mitochondrial function in men. Diabetes Care 2005;28:1636-42.
34. Yialamas MA., Dwyer AA., Hanley E., Lee H., Pitteloud N., Hayes FJ. Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2007;92:4254-9.
35. Traish AM., Miner MM., Morgentaler A., Zitzmann M. Testosterone deficiency. Am J Med 2011;124:578-87.
36. Mauras N., Hayes V., Welch S., Rini A., Helgeson K., Dokler M., Veldhuis JD., Urban RJ. Testosterone deficiency in young men: marked alterations in whole body protein kinetics., strength, and adiposity. J Clin Endocrinol Metab 1998;83:1886-92.
37. Ryu JW., Kim MS., Kim CH., Song KH., Park JY., Lee JD., Kim JB., Lee KU. DHEA administration increases brown fat uncoupling protein 1 levels in obese OLETF rats. Biochem Biophys Res Commun 2003;303:726-31.
38. Mootha VK., Lindgren CM., Eriksson KF., Subramanian A., Sihag S., Lehar J., Puigserver P., Carlsson E., Ridderstrale M., Laurila E., Houstis N., Daly MJ., Patterson N., Mesirov JP., Golub TR., Tamayo P., Spiegelman B., Lander ES., Hirschhorn JN., Altshuler D., Groop LC. PGC-1α-responsive genes involved in oxidative phospho-rylation are coordinately downregulated in human diabetes. Nat Genet 2003;34:267-73.
39. Patti ME., Butte AJ., Crunkhorn S., Cusi K., Berria R., Kashyap S., Miyazaki Y., Kohane I., Costello M., Saccone R., Landaker EJ., Goldfine AB., Mun E., DeFronzo R., Finlayson J., Kahn CR., Mandarino LJ. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc Natl Acad Sci USA 2003;100:8466-71.
40. Morino K., Petersen KF., Dufour S., Befroy D., Frattini J., Shatzkes N., Neschen S., White MF., Bilz S., Sono S., Pypaert M., Shulman GI. Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents. J Clin Invest 2005;115:3587-93.
41. Morino K., Petersen KF., Shulman GI. Molecular mechanisms of insulin resistance in humans and their potential links with mito-chondrial dysfunction. Diabetes 2006;55:S9-15.
42. Brooks DE. Influence of androgens on the weights of the male accessory reproductive organs and on the activities of mitochondrial enzymes in the epididymis of the rat. J Endocrinol 1979;82:293-303.
43. Collins TJ., Berridge MJ., Lipp P., Bootman MD. Mitochondria are morphologically and functionally heterogeneous within cells. EMBO J 2002;21:1616-27.
44. Koenig H., Goldstone A., Lu CY. Testosterone-mediated sexual dimorphism of the rodent heart. Ventricular lysosomes., mitochondria, and cell growth are modulated by androgens. Circ Res 1982;50:782-7.
45. Brooks DE. Activity and androgenic control of enzymes associated with the tricarboxylic acid cycle., lipid oxidation and mito-chondrial shuttles in the epididymis and epididymal spermatozoa of the rat. Biochem J 1978;174:741-52.
46. Ikeda Y., Aihara K., Akaike M., Sato T., Ishikawa K., Ise T., Yagi S., Iwase T., Ueda Y., Yoshida S., Azuma H., Walsh K., Tamaki T., Kato S., Matsumoto T. Androgen receptor counteracts Doxorubicin-induced cardiotoxicity in male mice. Mol Endocrinol 2010; 24:1338-48.
47. Fan W., Yanase T., Nomura M., Okabe T., Goto K., Sato T., Kawano H., Kato S., Nawata H. Androgen receptor null male mice develop late-onset obesity caused by decreased energy expenditure and lipolytic activity but show normal insulin sensitivity with high adiponectin secretion. Diabetes 2005;54:1000-8.
48. van Breda E., Keizer HA., Vork MM., Surtel DA., de Jong YF., van der Vusse GJ., Glatz JF. Modulation of fatty-acid-binding protein content of rat heart and skeletal muscle by endurance training and testosterone treatment. Pflugers Arch 1992;421: 274-9.
49. Costello LC., Franklin RB. Testosterone regulates pyruvate dehy-drogenase activity of prostate mitochondria. Horm Metab Res 1993;25:268-70.
50. Juang HH., Hsieh ML., Tsui KH. Testosterone modulates mito-chondrial aconitase in the full-length human androgen receptor-transfected PC-3 prostatic carcinoma cells. J Mol Endocrinol 2004;33:121-32.
51. Moon JS., Jin WJ., Kwak JH., Kim HJ., Yun MJ., Kim JW., Park SW., Kim KS. Androgen stimulates glycolysis for de novo lipid synthesis by increasing the activities of hexokinase 2 and 6-phos-phofructo-2-kinase/fructose-2,6-bisphosphatase 2 in prostate cancer cells. Biochem J 2011;433:225-33.
52. Czesla M., Mehlhorn G., Fritzsche D., Asmussen G. Cardio-myoplasty improvement of muscle fibre type transformation by anabolic steroid. J Mol Cell Cardiol 1997;29:2989-96.
53. Ustunel I., Akkoyunlu G., Demir R. The effect of testosterone on gastrocnemius muscle fibres in growing and adult male and female rats: a histochemical., morphometric and ultrastructural study. Anat Histol Embryol 2003;32:70-9.
54. Lanfranco F., Zitzmann M., Simoni M., Nieschlag E. Serum adiponectin levels in hypogonadal males: influence of testosterone replacement therapy. Clin Endocrinol (Oxf) 2004;60: 500-7.
55. Basaria S., Muller DC., Carducci MA., Egan J., Dobs AS. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 2006;106:581-8.
56. Mauvais-Jarvis F. Estrogen and androgen receptors: regulators of fuel homeostasis and emerging targets for diabetes and obesity. Trends Endocrinol Metab 2011;22:24-33.
57. Khaw KT., Barrett-Connor E. Lower endogenous androgens predict central adiposity in men. Ann Epidemiol 1992;2:675-82.
58. Lichtenstein MJ., Yarnell JW., Elwood PC., Beswick AD., Sweetnam PM., Marks V., Teale D., Riad-Fahmy D. Sex hormones., insulin, lipids., and prevalent ischemic heart disease. Am J Epidemiol 1987;126:647-57.
59. Pasquali R., Casimirri F., Cantobelli S., Melchionda N., Morselli Labate AM., Fabbri R., Capelli M., Bortoluzzi L. Effect of obesity and body fat distribution on sex hormones and insulin in men. Metabolism 1991;40:101-4.
60. Pasquali R., Casimirri F., Cantobelli S., Melchionda N., Morselli Labate AM., Fabbri R., Capelli M., Bortoluzzi L. Interrelation between plasma testosterone and plasma insulin in healthy adult men: the Telecom Study. Diabetologia 1992;35:173-7.
61. Andersson B., Marin P., Lissner L., Vermeulen A., Bjorntorp P. Testosterone concentrations in women and men with NIDDM. Diabetes Care 1994;17:405-11.
62. Barrett-Connor E. Lower endogenous androgen levels and dys-lipidemia in men with non-insulin-dependent diabetes mellitus. Ann Intern Med 1992;117:807-11.
63. Wang C., Jackson G., Jones TH., Matsumoto AM., NehraA, Perelman MA., Swerdloff RS., Traish A., Zitzmann M., Cunningham G. Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care 2011;34:1669-75.
64. Birkeland KI., Hanssen KF., Torjesen PA., Vaaler S. Level of sex hormone-binding globulin is positively correlated with insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab 1993;76:275-8.
65. Heufelder AE., Saad F., Bunck MC., Gooren L. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl 2009;30:726-33.
66. Boissonneault G. Evidence of apoptosis in the castration-induced atrophy of the rat levator ani muscle. Endocr Res 2001; 27:317-28.
67. Shukla Y., Prasad S., Tripathi C., Singh M., George J., Kalra N. In vitro and in vivo modulation of testosterone mediated alterations in apoptosis related proteins by [6]-gingerol. Mol Nutr Food Res 2007;51:1492-502.
68. Yang CY., Lam HC., Lee HC., Wei YH., Lu CC., Han TM., Tsai JL., Chuang YH., Lee JK. MELAS syndrome associated with diabetes mellitus and hyperthyroidism: a case report from Taiwan. Clin Endocrinol (Oxf) 1995;43:235-9.
69. Traish A., Kim N. The physiological role of androgens in penile erection: regulation of corpus cavernosum structure and function. J Sex Med 2005;2:759-70.
70. Niki E. Antioxidants in relation to lipid peroxidation. Chem Phys Lipids 1987;44:227-53.
71. Koenig H., Goldstone A., Lu CY. Androgens regulate mitochon-drial cytochrome c oxidase and lysosomal hydrolases in mouse skeletal muscle. Biochem J 1980;192:349-53.
72. Koenig H., Goldstone A., Blume G., Lu CY. Testosterone-mediated sexual dimorphism of mitochondria and lysosomes in mouse kidney proximal tubules. Science 1980;209:1023-6.
73. Beauchemin AM., Gottlieb B., Beitel LK., Elhaji YA., Pinsky L., Trifiro MA. Cytochrome c oxidase subunit Vb interacts with human androgen receptor: a potential mechanism for neurotoxicity in spinobulbar muscular atrophy. Brain Res Bull 2001;56:285-97.
74. Wang CH., Wang CC., Wei YH. Mitochondrial dysfunction in insulin insensitivity: implication of mitochondrial role in type 2 diabetes. Ann N Y Acad Sci 2010;1201:157-65.
75. Mårin P., Lönn L., Andersson B., Odén B., Olbe L., Bengtsson BA., Björntorp P. Assimilation of triglycerides in subcutaneous and intraabdominal adipose tissues in vivo in men: effects of testosterone. J Clin Endocrinol Metab 1996;81:1018-22.
76. Christofilis MA., Remacle-Bonnet M., Atlan-Gepner C., Garrouste F., Vialettes B., Fuentes P., Guidicelli R., Pommier G. Study of serum big-insulin-like growth factor (IGF)-II and IGF binding proteins in two patients with extrapancreatic tumor hypoglyce-mia, using a combination of Western blotting methods. Eur J Endocrinol 1998;139:317-22.
77. Saleh J., Sniderman AD., Cianflone K. Regulation of plasma fatty acid metabolism. Clin Chim Acta 1999;286:163-80.
78. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997;46:3-10.
79. McGarry JD., Dobbins RL., Stein DT. [Fatty acids., insulin resistance and pancreatic β cell function]. J Annu Diabetol Hotel Dieu 1998;1-10. PMID: 9773605.
80. Peeters RA., Veerkamp JH. Does fatty acid-binding protein play a role in fatty acid transport? Mol Cell Biochem 1989;88:45-9.
81. Nishizawa H., Shimomura I., Kishida K., Maeda N., Kuriyama H., Nagaretani H., Matsuda M., Kondo H., Furuyama N., Kihara S., Nakamura T., Tochino Y., Funahashi T., Matsuzawa Y. Androgens decrease plasma adiponectin., an insulin-sensitizing adipocyte-derived protein. Diabetes 2002;51:2734-41.
82. Bojesen A., Kristensen K., Birkebaek NH., Fedder J., Mosekilde L., Bennett P., Laurberg P., Frystyk J., Flyvbjerg A., Christiansen JS., Gravholt CH. The metabolic syndrome is frequent in Klinefelter's syndrome and is associated with abdominal obesity and hypogo-nadism. Diabetes Care 2006;29:1591-8.
83. Phillips GB. Relationship between serum sex hormones and glucose., insulin and lipid abnormalities in men with myocardial infarction. Proc Natl Acad Sci USA 1977;74:1729-33.
84. Seidell JC., Bjorntorp P., Sjostrom L., Kvist H., Sannerstedt R. Visceral fat accumulation in men is positively associated with insulin., glucose, and C-peptide levels., but negatively with testosterone levels. Metabolism 1990;39:897-901.
85. Abate N., Haffner SM., Garg A., Peshock RM., Grundy SM. Sex steroid hormones., upper body obesity., and insulin resistance. J Clin Endocrinol Metab 2002;87:4522-7.
86. Kelley DE., He J., Menshikova EV., Ritov VB. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 2002;51:2944-50.
87. Ritov VB., Menshikova EV., He J., Ferrell RE., Goodpaster BH., Kelley DE. Deficiency of subsarcolemmal mitochondria in obesity and type 2 diabetes. Diabetes 2005;54:8-14.
88. Simoneau JA., Kelley DE. Altered glycolytic and oxidative capacities of skeletal muscle contribute to insulin resistance in NIDDM. J Appl Physiol 1997;83:166-71.
89. Ukropcova B., Sereda O., de Jonge L., Bogacka I., Nguyen T., Xie H., Bray GA., Smith SR. Family history of diabetes links impaired substrate switching and reduced mitochondrial content in skeletal muscle. Diabetes 2007;56:720-7.
90. Heilbronn LK., Gan SK., Turner N., Campbell LV., Chisholm DJ. Markers of mitochondrial biogenesis and metabolism are lower in overweight and obese insulin-resistant subjects. J Clin Endocrinol Metab 2007;92:1467-73.
91. Mensink M., Hesselink MK., Russell AP., Schaart G., Sels JP., Schrauwen P. Improved skeletal muscle oxidative enzyme activity and restoration of PGC-1a and PPARp/S gene expression upon rosiglitazone treatment in obese patients with type 2 diabetes mellitus. Int J Obes (Lond) 2007;31:1302-10.
92. Ritov VB., Menshikova EV., Azuma K., Wood R., Toledo FG., Goodpaster BH., Ruderman NB., Kelley DE. Deficiency of electron transport chain in human skeletal muscle mitochondria in type 2 diabetes mellitus and obesity. Am J Physiol Endocrinol Metab 2010;298:E49-58.
93. Liang P., Hughes V., Fukagawa NK. Increased prevalence of mito-chondrial DNA deletions in skeletal muscle of older individuals with impaired glucose tolerance: possible marker of glycemic stress. Diabetes 1997;46:920-3.
94. Petersen KF., Dufour S., Befroy D., Garcia R., Shulman GI. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 2004;350:664-71.
95. Mogensen M., Sahlin K., Fernström M., Glintborg D., Vind BF., Beck-Nielsen H., H.Ø. Øjlund K. Mitochondrial respiration is decreased in skeletal muscle of patients with type 2 diabetes. Diabetes 2007;56:1592-9.
96. Mogensen M., Sahlin K., Fernström M., Glintborg D., Vind BF., Beck-Nielsen H., H.Ø. Øjlund K. Mitochondria are impaired in the adipocytes of type 2 diabetic mice. Diabetologia 2006;49: 784-91.
97. Erol A. Insulin resistance is an evolutionarily conserved physiological mechanism at the cellular level for protection against increased oxidative stress. Bioessays 2007;29:811-8.
98. Evans JL. The secret life of mitochondria. Your cells' microscopic powerhouses for longevity., appearance and performance. Xymogen EP., 2009.
99. Conley KE., Marcinek DJ., Villarin J. Mitochondrial dysfunction and age. Curr Opin Clin Nutr Metab Care 2007;10:688-92.
100. Conley KE., Jubrias SA., Esselman PC. Oxidative capacity and ageing in human muscle. J Physiol 2000;526:203-10.
101. Jubrias SA., Esselman PC., Price LB., Cress ME., Conley KE. Large energetic adaptations of elderly muscle to resistance and endurance training. J Appl Physiol 2001;90:1663-70.
102. Hotta K., Funahashi T., Arita Y., Takahashi M., Matsuda M., Okamoto Y., Iwahashi H., Kuriyama H., Ouchi N., Maeda K., Nishida M., Kihara S., Sakai N., Nakajima T., Hasegawa K., Muraguchi M., Ohmoto Y., Nakamura T., Yamashita S., Hanafusa T., Matsuzawa Y. Plasma concentrations of a novel., adipose-specific protein., adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000;20:1595-9.
103. Li K., Li L., Yang GY., Liu H., Li SB., Boden G. Effect of short hairpin RNA-mediated adiponectin/Acrp30 down-regulation on insulin signaling and glucose uptake in the 3T3-L1 adipocytes. J Endocrinol Invest 2010;33:96-102.
104. Koh EH., Park JY., Park HS., Jeon MJ., Ryu JW., Kim M., Kim SY., Kim MS., Kim SW., Park IS., Youn JH., Lee KU. Essential role of mitochondrial function in adiponectin synthesis in adipocytes. Diabetes 2007;56:2973-81.
105. Petersen KF., Befroy D., Dufour S., Dziura J., Ariyan C., Rothman DL., DiPietro L., Cline GW., Shulman GI. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 2003;300:1140-2.
106. Wisløff U., Najjar SM., Ellingsen O., Haram PM., Swoap S., Al-Share Q., Fernstrom M., Rezaei K., Lee SJ., Koch LG., Britton SL. Cardiovascular risk factors emerge after artificial selection for low aerobic capacity. Science 2005;307:418-20.
107. Beato M. Gene regulation by steroid hormones. Cell 1989;56:335-44.
108. Foradori CD., Weiser MJ., Handa RJ. Non-genomic actions of androgens. Front Neuroendocrinol 2008;29:169-81.
109. Lin Y., Kokontis J., Tang F., Godfrey B., Liao S., Lin A., Chen Y., Xiang J. Androgen and its receptor promote Bax-mediated apoptosis. Mol Cell Biol 2006;26:1908-16.
110. Er F., Michels G., Gassanov N., Rivero F., Hoppe UC. Testosterone induces cytoprotection by activating ATP-sensitive K+ channels in the cardiac mitochondrial inner membrane. Circulation 2004;110:3100-7.
111. Akimoto T., Ribar TJ., Williams RS., Yan Z. Skeletal muscle adaptation in response to voluntary running in Ca2+/calmodulin-dependent protein kinase IV-deficient mice. Am J Physiol Cell Physiol 2004;287:C1311-9.
112. Bergeron R., Ren JM., Cadman KS., Moore IK., Perret P., Pypaert M., Young LH., Semenkovich CF., Shulman GI. Chronic activation of AMP kinase results in NRF-1 activation and mitochondrial biogenesis. Am J Physiol Endocrinol Metab 2001;281:E1340-6.
113. Winder WW., Holmes BF., Rubink DS., Jensen EB., Chen M., Holloszy JO. Activation of AMP-activated protein kinase increases mitochondrial enzymes in skeletal muscle. J Appl Physiol 2000;88:2219-26.
114. Scarpulla RC. Nuclear control of respiratory gene expression in mammalian cells. J Cell Biochem 2006;97:673-83.
115. Niemann B., Chen Y., Teschner M., Li L., Silber RE., Rohrbach S. Obesity induces signs of premature cardiac aging in younger patients: the role of mitochondria. J Am Coll Cardiol 2011;57:577-85.
116. Abel ED. Obesity stresses cardiac mitochondria even when you are young. J Am Coll Cardiol 2011;57:586-589.
117. Gavrilova-Jordan LP., Price TM. Actions of steroids in mitochondria. Semin Reprod Med 2007;25:154-64.
118. Psarra AM., Sekeris CE. Steroid and thyroid hormone receptors in mitochondria. IUBMB Life 2008;60:210-23.
119. Scheller K., Sekeris CE. The effects of steroid hormones on the transcription of genes encoding enzymes of oxidative phosphorylation. Exp Physiol 2003;88:129-40.
120. Scarpulla RC. Nuclear control of respiratory chain expression in mammalian cells. J Bioenerg Biomembr 1997;29: 109-19.
121. Pillar TM., Seitz HJ. Thyroid hormone and gene expression in the regulation of mitochondrial respiratory function. Eur J Endocrinol 1997;136:231-9.
122. Park SY., Lee W. The depletion of cellular mitochondrial DNA causes insulin resistance through the alteration of insulin receptor substrate-1 in rat myocytes. Diabetes Res Clin Pract 2007;77:S165-71.
123. Lim JH., Lee JI., Suh YH., Kim W., Song JH., Jung MH. Mitochondrial dysfunction induces aberrant insulin signalling and glucose utilisation in murine C2C12 myotube cells. Diabetologia 2006;49:1924-36.